Mark Sirgo Biography and Net Worth

Director of 9 Meters Biopharma

Dr. Sirgo is Chief Executive Officer of Aruna Bio. Dr. Sirgo brings over 35 years of pharmaceutical experience to the Board from preclinical development through global product commercialization. Most recently, Dr. Sirgo served 13 years as President and CEO of BioDelivery Sciences International (Nasdaq:BDSI), a specialty pharmaceutical company focused in CNS/pain. While leading BDSI, Dr. Sirgo was successful in raising nearly $600 million in capital through partnerships and financings to support the development, FDA approval and commercial launch of three products utilizing the company’s proprietary drug delivery technology. Prior to BDSI, Dr. Sirgo held increasing roles at GSK culminating in Vice President of Clinical Development as well as Senior Vice President of Sales and Marketing for Pharmaceutical Product Development (PPD). Dr. Sirgo served on the Board of Salix, Inc (Nasdaq: SLXP) prior to the sale to Valeant in 2015 and is currently on the Boards of BDSI, Biomerica (Nasdaq:BMRA) and Aruna Bio.

What is Mark A. Sirgo's net worth?: The estimated net worth of Mark A. Sirgo is at least $0.00 as of July 1st, 2022. Dr. Sirgo owns 1,454,045 shares of 9 Meters Biopharma stock worth more than $0 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Sirgo may own. Learn More about Mark A. Sirgo's net worth.
How do I contact Mark A. Sirgo?: The corporate mailing address for Dr. Sirgo and other 9 Meters Biopharma executives is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. 9 Meters Biopharma can also be reached via phone at (919) 275-1933 and via email at [email protected]. Learn More on Mark A. Sirgo's contact information.
Has Mark A. Sirgo been buying or selling shares of 9 Meters Biopharma?: Mark A. Sirgo has not been actively trading shares of 9 Meters Biopharma during the last ninety days. Most recently, on Friday, July 1st, Mark A. Sirgo bought 175,000 shares of 9 Meters Biopharma stock. The stock was acquired at an average cost of $0.25 per share, with a total value of $43,750.00. Following the completion of the transaction, the director now directly owns 1,454,045 shares of the company's stock, valued at $363,511.25. Learn More on Mark A. Sirgo's trading history.
Who are 9 Meters Biopharma's active insiders?: 9 Meters Biopharma's insider roster includes Michael Constantino (Director), Mark Sirgo (Director), Edward Sitar (CFO), and John Temperato (CEO). Learn More on 9 Meters Biopharma's active insiders.

Mark A. Sirgo Insider Trading History at 9 Meters Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2022	Buy	175,000	$0.25	$43,750.00	1,454,045
3/3/2022	Buy	86,450	$0.58	$50,141.00
12/2/2021	Buy	50,000	$0.89	$44,500.00
11/18/2021	Buy	20,000	$1.06	$21,200.00
9/7/2021	Buy	73,529	$1.36	$99,999.44
8/20/2021	Buy	25,000	$1.10	$27,500.00
4/5/2021	Buy	300,000	$1.00	$300,000.00	1,074,066
9/10/2020	Buy	50,000	$0.60	$30,000.00	461,784
8/17/2020	Buy	100,000	$0.56	$56,000.00	411,784

Mark A. Sirgo Buying and Selling Activity at 9 Meters Biopharma

9 Meters Biopharma Company Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

46 shs

Average Volume

315,915 shs

Market Capitalization

$1.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share

From Darwin | Ad

👉[Click here to get your FREE report delivered instantly!]